CDT Equity (CDT) Change in Account Payables (2022 - 2026)
CDT Equity's (CDT) quarterly Change in Account Payables came in at $532000.0 in Q1 2026, up 173.79% YoY from $194312.1 in Q1 2025, and down 58.24% on a QoQ basis from $1.3 million in Q4 2025.
CDT Equity (CDT) Change in Account Payables (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Change in Account Payables data on file, last reported at $532000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 173.79% year-over-year to $532000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 180.7% YoY) and the FY2025 annual result came in at $434000.0, down 64.57% from the prior year.
- Change in Account Payables slipped to $532000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.3 million in Q4 2025 to a low of -$721000.0 in Q1 2025.
- A 5-year average of $218534.1 and a median of $209000.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 404.06% in 2025, down 643.3% in 2025.
- Tracing CDT's Change in Account Payables over 5 years: stood at $3875.0 in 2022, then jumped by 5293.55% to $209000.0 in 2023, then sank by 300.48% to -$419000.0 in 2024, then jumped by 404.06% to $1.3 million in 2025, then plunged by 58.24% to $532000.0 in 2026.
- The last three Change in Account Payables figures came in at $532000.0 (Q1 2026), $1.3 million (Q4 2025), and -$604000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | 1.27 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | -604,000.00 |
| Sep 30, 2025 | -604,000.00 |
| Jun 30, 2025 | 485,000.00 |
| Jun 30, 2025 | 485,000.00 |
| Mar 31, 2025 | -721,000.00 |
| Mar 31, 2025 | -721,000.00 |
| Dec 31, 2024 | -419,000.00 |
| Dec 31, 2024 | -419,000.00 |
| Sep 30, 2024 | 833,000.00 |
| Sep 30, 2024 | 833,000.00 |
| Jun 30, 2024 | 908,000.00 |
| Jun 30, 2024 | 908,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Mar 31, 2024 | -97,000.00 |